Expression of c-kit protein and mutational status of the c-kit gene in osteosarcoma and their clinicopathological significance

Journal of International Medical Research

Volumn 36, Issue 5, 2008, Pages 1008-1014

  Wei, H ^a,d   Zhao, M Q ^a   Dong, W ^b   Yang, Y ^c   Li, Jin Song ^a  

^a SHANDONG UNIVERSITY   (China)

^b Weifang Chinese Medicine Hospital   (China)

^c Department of Pathology   (China)

^d Jining College   (China)

Author keywords

C KIT expression; C KIT mutations; Molecularly targeted therapy; Osteosarcoma; Prognosis; Tyrosine kinase inhibitors

Indexed keywords

STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EXON; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL TIME; ADOLESCENT; ADULT; CHILD; FEMALE; GENETICS; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; OSTEOSARCOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL RATE;

EID: 54449083631     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600518     Document Type: Article

References (23)

1. Baserga R: Oncogenes and the strategy of growth factors. Cell 1994; 79: 927-930.
2. Reilly JT: Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol 2002; 116: 744-757.
3. Longley BJJ, Metcalfe DD, Tharp M, et al: Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609-1614.
4. Lux ML, Rubin BP, Biase TL, et al: Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-795.
5. Broudy VC, Smith SO, Lin N, et al: Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood 1992; 80: 60-67.
6. Ohashi A, Funasaka Y, Ueda M, et al: c-kit receptor expression in cutaneous malignant melanoma and benign melanotic naevi. Melanoma Res 1996; 6: 25-30.
7. Tonary AM, Macdonald EA, Faught W, et al: Lack of expression of c-kit in ovarian cancers is associated with poor prognosis. Int J Cancer 2000; 89: 242-250.
8. Hines SJ, Organ C, Kornstein MJ, et al: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 1995; 6: 769-779.
9. Arber DA, Tamayo R, Weiss LM: Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998; 29: 498-504.
10. Entz-Werlé N, Marcellin L, Gaub MP, et al: Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcoma. J Clin Oncol 2005; 23: 2248-2255.
11. Turner AM, Zsebo KM, Martin F, et al: Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992; 80: 374-381.
12. Tian Q, Frierson HFJ, Krystal GW, et al: Activating c-kit gene mutations in human germ-cell tumors. Am J Pathol 1999; 154: 1643-1647.
13. Di Paola RS, Kuczynski WI, Onodera, K, et al: Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther 1997; 4: 176-182.
14. Ingram DA, Yang FC, Travers JB, et al: Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 2000; 191: 181-188.
15. Sulzbacher I, Birner P, Toma C, et al: Expression of c-kit in human osteosarcoma and its relevance as prognostic parameter. J Clin Pathol 2007; 60: 804-807.
16. Schajowicz F, Sissons HA, Sobin LH: The World Health Organization's histologic classification of bone tumors. A commentary on the second edition. Cancer 1995; 75: 1208-1214.
17. Duhlin DC, Coventry MB: Osteogenic sarcoma: a study of six hundred cases. J Bone Joint Surg 1967; 49: 101-110.
18. London SJ, Xia J, Lehman TA, et al: Collection of buccal cell DNA in seventh-grade children using water and a toothbrush. Cancer Epidemiol Biomarkers Prev 2001; 10: 1227-1230.
19. Ishikubo T, Akagi K, Kurosumi M, et al: Immunohistochemical and mutational analysis of c-kit in gastrointestinal neuroendocrine cell carcinoma. Jpn J Clin Oncol 2006; 36: 494-498.
20. Smithey BE, Pappo AS, Hill DA: C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 2002; 26: 486-492.
21. Longley BJ, Reguera MJ, Ma Y: Classes of c-KIT activating mutation: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001; 25: 571-576.
22. Ma Y, Zeng S, Metcalfe DD, et al: The c-KIT mutation causing human mastrocytosis is resistant to ST1571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741-1744.
23. Ma Y, Cunningham M, Wang X, et al: Inhibition of spontaneous receptor phosphorylation by residues in a putative α-helix in the KIT intracellular juxta membrane region. J Biol Chem 1999; 274: 13399-13402.